Drug
Pasireotide Diaspartate
Pasireotide Diaspartate: highest development phase Phase 2, developed by Recordati. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Recordati
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pasireotide Diaspartate NCT05928390 | Phase 2 | Post-Bariatric Hypoglycemia |
Latest
No recent events.
Follow Pasireotide Diaspartate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.